1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. MAINZ BIOMED N.V.
Mainz Biomed N.V.
XNAS: QUCY
Download real time
1.36 -0.07 (-4.90%)
72.41% Fall from 52W High
710.7K
XNAS Volume

XNAS 10 Jul, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for Mainz Biomed N.V.

The latest disclosure was made by Peter M. O’Rourke in Mainz Biomed N.V. where a trade of 112,859 Stock Option (Right to Buy) done was reported to US exchanges on July 6, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Peter M. O’Rourke Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Jul 2026 112,859 112,859 - - Stock Option (Right to Buy)
David Natan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 May 2026 137,141 137,141 - 0 Ordinary Shares
David Elliot Lazar Director, Chief Executive Officer, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Apr 2026 1,000,000 1,000,000 - - Series D Preferred Shares
David Elliot Lazar Director, Chief Executive Officer, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Apr 2026 1,000,000 1,000,000 - - Series E Preferred Shares
Heiner Dreismann Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 45,000 64,700 - 0 Ordinary Shares
Gregory J. Tibbitts Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 45,000 55,875 - 0 Ordinary Shares
William J. Caragol Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 290,000 367,899 - 0 Ordinary Shares
Guido Baechler Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 440,000 605,058 - 0 Ordinary Shares
David Elliot Lazar Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 1,000,000 1,000,000 - - Series B Preferred Shares
David Elliot Lazar Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 1,000,000 1,000,000 - - Series A Preferred Shares
David Elliot Lazar Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2026 1,000,000 1,000,000 - - Series C Preferred Shares
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters